In a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Evaluating ixazomib, cyclophosphamide and dexamethasone treatment for relapsed/refractory multiple myeloma
In a nutshell This article investigated the safety and effectiveness of combining ixazomib (Ninlaro), cyclophosphamide (Cytoxan) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the combination treatment is safe and gave...
Read MoreEvaluating a new targeted therapy with or without itacitinib for relapsed or refractory lymphoma
In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read MoreSearching for patients with castration resistant metastatic prostate cancer to test cabazitaxel and abiraterone
In a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...
Read MoreEvaluating long-term outcomes of ibrutinib for relapsed or refractory mantle cell lymphoma
In a nutshell This study evaluated the long-term outcomes of ibrutinib (Imbruvica) treatment in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib is effective and well-tolerated in these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s...
Read MoreSearching for patients with relapsed or refractory non-Hodgkin lymphoma to try a new drug
In a nutshell This study is evaluating the safety and effectiveness of a new drug called lisocabtagene maraleucel compared to standard chemotherapy for relapsed (recurrent) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be time to any disease-related complication. The...
Read MoreThe safety and effectiveness of bosutinib in patients with chronic myeloid leukemia
In a nutshell This study looked at the safety and effectiveness of bosutinib (Bosulif) in the treatment of chronic myeloid leukemia (CML). Researchers found that bosutinib was effective in patients who have failed other similar drug treatments. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This can lead to abnormal...
Read MoreIs Daratumumab added to bortezomib plus dexamethasone better in treating multiple myeloma?
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and gave the greatest benefit to...
Read MoreAdding inotuzumab ozogamicin with or without blinatumomab to chemotherapy for ALL.
In a nutshell This study looked at the effectiveness of adding inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) to low-intensity chemotherapy in the treatment of ALL. Researchers found that this combination of treatment was effective in these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow. This...
Read MoreIs blinatumomab safe and effective in the treatment of ALL?
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) in the treatment of unresponsive acute lymphoblastic leukemia (ALL). Researchers found that blinatumomab was safe and effective in the treatment of these patients. Some background Acute lymphoblastic leukemia is a type of cancer of the bone marrow. This can lead...
Read MoreIs regorafenib a safe option for the treatment of metastatic colorectal cancer?
In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients. Some background The standard treatment...
Read MoreEvaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma
In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...
Read More
